Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer

Abstract

Mutated or rearranged driver kinases in non-small cell lung cancer (NSCLC) cells are clinically amenable to treatment with tyrosine kinase inhibitors (TKIs) resulting in prolonged survival and significant benefit compared to cytotoxic chemotherapy. The most frequent genomic alterations are observed for epidermal growth factor receptor and anaplastic lymphoma kinase, which can be blocked by a range of specific TKIs in sequence. In clinics, resistance to TKIs emerges after approximately one year and comprises secondary mutations of the kinases (on-target) or alternative pathways circumventing the original kinase (off-target) alterations. A special feature of NSCLC is the occurrence of histological transformation to small cell lung cancer (SCLC) in up to 14% of cases, which, in general, is accompanied by resistance to the original TKIs. SCLC transformed tumors may be treated with the classical platinum/etoposide regimen but thus far there are no definitive guidelines. Four transformed pleural SCLC lines in our lab indicate the presence of a gradual NSCLC-SCLC shift with overlapping drug sensitivities. In conclusion, the treatment of NSCLC-SCLC transformed cancer cells would need a better chemosensitivity assessment using functional genomics to guide further therapy.

Keywords

Lung cancer / non-small cell lung cancer / small cell lung cancer / transformation / epidermal growth factor receptor / tyrosine kinase inhibitor / chemotherapy / drug resistance

References

[1] Recondo G,Olaussen KA,Friboulet L.Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?.Nat Rev Clin Oncol2018;15:694-708

[2] Bhullar KS,McGowan EM,Jha A.Kinase-targeted cancer therapies: progress, challenges and future directions..Mol Cancer2018;17:48 PMCID:PMC5817855

[3] Zappa C.Non-small cell lung cancer: current treatment and future advances..Transl Lung Cancer Res2016;5:288-300 PMCID:PMC4931124

[4] Sukrithan V,Barbaro A.Emerging drugs for EGFR-mutated non-small cell lung cancer..Expert Opin Emerg Drugs2019;24:5-16

[5] Camidge DR,Sequist LV.Acquired resistance to TKIs in solid tumours: learning from lung cancer..Nat Rev Clin Oncol2014;11:473-81

[6] Santoni-Rugiu E,Urbanska EM,Stricker K.Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance..Cancers (Basel)2019;11: PMCID:PMC6678669

[7] Ahn MJ,Shepherd FA,Sequist LV.Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies..Cancer2019;125:892-901

[8] Blakely CM,Wu W,Chabon JJ.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers..Nat Genet2017;49:1693-704 PMCID:PMC5709185

[9] Oser MG,Sequist LV.Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin..Lancet Oncol2015;16:e165-72 PMCID:PMC4470698

[10] Murtuza A,Shen JP,Woodward BD.Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer..Cancer Res2019;79:689-98

[11] Sequist LV,Dias-Santagata D,Turke AB.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR Inhibitors..Sci Transl Med2011;3:75ra26 PMCID:PMC3132801

[12] Jiao Q,Ren Y,Wang Q.Advances in studies of tyrosine kinase inhibitors and their acquired resistance..Mol Cancer2018;17:36 PMCID:PMC5817861

[13] Hochmair MJ,Schwab S,Prosch H.Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib..Target Oncol2019;14:75-83 PMCID:PMC6403194

[14] Thress KS,Felip E,Stetson D.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M..Nat Med2015;21:560-2 PMCID:PMC4771182

[15] Tomasello C,Napolitano M,Grizzi G.Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives..Crit Rev Oncol Hematol2018;123:149-61

[16] Yu HA,Jordan E,Ni A.Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance..Clin Cancer Res2018;24:3108-18 PMCID:PMC6420806

[17] Lee JK,Kim S,Youk J.Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas..J Clin Oncol2017;35:3065-74

[18] Ahn S,Han J,Lee SH.Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases..J Pathol Transl Med2016;50:258-63 PMCID:PMC4963973

[19] Dorantes-Heredia R,Cano-García F.Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors..Transl Lung Cancer Res2016;5:401-12 PMCID:PMC5009079

[20] Schoenfeld AJ,Rizvi H,Daneshbod Y.Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers..J Clin Oncol2019;37:9028

[21] Girard N.Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates..Future Oncol2019;15:2983-97

[22] Tsui DWY,Wong ASC,Smith CG.Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer..EMBO Mol Med2018;10: PMCID:PMC5991591

[23] Ferrer L,Brevet M,Mazieres J.A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics..J Thorac Oncol2019;14:130-4

[24] Niederst MJ,Poirier JT,Lockerman EL.RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer..Nat Comm2015;6:6377 PMCID:PMC4357281

[25] van Meerbeeck JP,De Ruysscher DK.Small-cell lung cancer..Lancet2011;378:1741-55

[26] Marcoux N,O’Kane G,Neal JW.EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes..J Clin Oncol2019;37:278-85 PMCID:PMC7001776

[27] George J,Jang SJ,Ozretić L.Comprehensive genomic profiles of small cell lung cancer..Nature2015;524:47-53 PMCID:PMC4861069

[28] Kim Y,Shim JH,Park WY.Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC..J Thorac Oncol2019;14:193-202

[29] Lin CA,Chen HY,Lin SU.EGFR-mutant SCLC exhibits heterogeneous phenotypes and resistance to common antineoplastic drugs..J Thorac Oncol2019;14:513-26

[30] Sutherland KD,Brouns I,Song JY.Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung..Cancer Cell2011;19:754-64

[31] Park CK,Kim YC.Is transformed small cell lung cancer (SCLC) different from de novo SCLC?.Transl Cancer Res2019;8:346-9

[32] Shao Y.Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors..Int J Clin Oncol2018;23:235-42

[33] Roca E,Amoroso V,Ferrari V.Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis..Cancer Treat Rev2017;59:117-22

[34] Sharma S,Das K,Barnaby K.Small cell transformation: an increasingly common mechanism of resistance in EGFR-mutated lung cancer..J Target Ther Cancer2018;

[35] Suda K,Sakai K,Shimizu S.Small cell lung cancer transformation and T790M mutation: complementary roles in acquired resistance to kinase inhibitors in lung cancer..Sci Rep2015;5:14447 PMCID:PMC4585860

[36] Ham JS,Kim HK,Sun JM.Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment..J Thorac Oncol2016;11:e1-4

[37] Oh HJ,Kim KH,Shin HJ.Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer..J Thorac Dis2016;8:2530-7 PMCID:PMC5059255

[38] Santoni-Rugiu E.Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma..Precis Cancer Med2019;2:5

[39] Farago AF,Sequist LV.Unlocking the mystery of small-cell lung transformations in EGFR mutant adenocarcinoma..J Clin Oncol2017;35:2987-8

[40] Manca P,Pantano F,Santini D.Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib..Oncotarget2017;8:59986-90 PMCID:PMC5601795

[41] Araki J,Suto R,Sasaki J.Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer..Lung Cancer2005;48:141-4

[42] Shiao TH,Yu CJ,Hsu YC.Epidermal growth factor receptor mutations in small cell lung cancer: a brief report..J Thorac Oncol2011;6:195-8

[43] Lee S,Kwak M,Chon S.Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report..Onco Targets Ther2018;11:3943-7 PMCID:PMC6042494

[44] Hamilton G.Role of circulating tumor cell spheroids in drug resistance..Cancer Drug Resist2019;2:762-72

[45] Terzuoli E,Ciccone V,Morbidelli L.mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines..Prostaglandins Other Lipid Mediat2019;143:106344

[46] Hamilton G,Plangger A.Implementation of functional precision medicine for anaplastic lymphoma kinase-rearranged non-small lung cancer..Precis Cancer Med2019;2:19